AXNX Axonics Inc

Price (delayed)

$68.085

Market cap

$3.45B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.23

Enterprise value

$3.3B

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of BulkamidĀ®, offers ...

Highlights
AXNX's EPS has soared by 86% year-on-year and by 65% since the previous quarter
The net income has soared by 84% YoY and by 63% from the previous quarter
AXNX's quick ratio has surged by 74% year-on-year but it is down by 6% since the previous quarter

Key stats

What are the main financial stats of AXNX
Market
Shares outstanding
50.66M
Market cap
$3.45B
Enterprise value
$3.3B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.63
Price to sales (P/S)
9.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.65
Earnings
Revenue
$342.56M
EBIT
-$14.06M
EBITDA
-$1.88M
Free cash flow
-$871,000
Per share
EPS
-$0.23
Free cash flow per share
-$0.02
Book value per share
$12.1
Revenue per share
$6.96
TBVPS
$9.85
Balance sheet
Total assets
$660.75M
Total liabilities
$50.13M
Debt
$2.85M
Equity
$610.62M
Working capital
$439.79M
Liquidity
Debt to equity
0
Current ratio
13.36
Quick ratio
11.06
Net debt/EBITDA
76.77
Margins
EBITDA margin
-0.5%
Gross margin
74.4%
Net margin
-3.5%
Operating margin
-9%
Efficiency
Return on assets
-1.8%
Return on equity
-2%
Return on invested capital
-5.8%
Return on capital employed
-2.2%
Return on sales
-4.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXNX stock price

How has the Axonics stock price performed over time
Intraday
-0.55%
1 week
-0.07%
1 month
-0.2%
1 year
13.31%
YTD
9.41%
QTD
9.41%

Financial performance

How have Axonics's revenue and profit performed over time
Revenue
$342.56M
Gross profit
$254.76M
Operating income
-$30.73M
Net income
-$12M
Gross margin
74.4%
Net margin
-3.5%
The company's net margin has surged by 89% YoY and by 65% QoQ
The net income has soared by 84% YoY and by 63% from the previous quarter
The operating margin has surged by 73% year-on-year and by 38% since the previous quarter
The company's operating income has surged by 61% YoY and by 34% QoQ

Growth

What is Axonics's growth rate over time

Valuation

What is Axonics stock price valuation
P/E
N/A
P/B
5.63
P/S
9.79
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.65
AXNX's EPS has soared by 86% year-on-year and by 65% since the previous quarter
The P/B is 18% above the last 4 quarters average of 4.8 but 4.1% below the 5-year quarterly average of 5.9
AXNX's equity is up by 11% year-on-year
The price to sales (P/S) is 84% lower than the 5-year quarterly average of 62.4 but 11% higher than the last 4 quarters average of 8.9
The revenue has increased by 42% year-on-year and by 7% since the previous quarter

Efficiency

How efficient is Axonics business performance
AXNX's ROIC has soared by 91% YoY and by 63% QoQ
AXNX's ROS has soared by 87% year-on-year and by 60% since the previous quarter
The ROE has soared by 87% YoY and by 64% from the previous quarter
AXNX's ROA has soared by 87% YoY and by 63% from the previous quarter

Dividends

What is AXNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXNX.

Financial health

How did Axonics financials performed over time
Axonics's current ratio has soared by 81% YoY but it has decreased by 6% from the previous quarter
AXNX's quick ratio has surged by 74% year-on-year but it is down by 6% since the previous quarter
The company's debt is 100% lower than its equity
AXNX's debt to equity has dropped by 100% year-on-year
The company's debt has shrunk by 70% YoY and by 4.1% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.